About FullTerm^™, The Fetal Fibronectin Test

FullTerm, The Fetal Fibronectin Test, is a simple, safe, non-invasive test that can help you identify which of your patients are at risk of having a preterm birth so you can consider the appropriate intervention. The test is used in more than 80% of major U.S. obstetric teaching institutions, and is cited in more than 150 peer-reviewed publications. The use of FullTerm, The Fetal Fibronectin Test, has been recommended by ACOG, studied by the NIH, and approved by the FDA.

FullTerm, The Fetal Fibronectin Test, is used for the early prediction of preterm birth risk from 22 to 35 weeks of pregnancy. It can help you assess the risk of preterm birth in women with or without symptoms

FullTerm, The Fetal Fibronectin Test, is the most powerful predictor of preterm birth <32 weeks.¹ A negative or a positive test result can help you better manage your patients' pregnancies.

FullTerm, The Fetal Fibronectin Test, is non-invasive and similar to a Pap test. It can be given in your office or in the hospital. Use of FullTerm, The Fetal Fibronectin Test, has been shown to reduce overall admissions for preterm labor and charges per admission.

For your patients who are at risk for preterm delivery, with or without symptoms, FullTerm, The Fetal Fibronectin Test, can help you determine the appropriate level of intervention.

In many cases, results of FullTerm, The Fetal Fibronectin Test, may help you avoid unnecessary interventions. In others, it will help you identify which of your patients require more careful management and added attention.

Patients and colleagues who have used FullTerm, The Fetal Fibronectin Test, share their perspectives.

Reference

• 1. Goldenberg RL, Iams JD, Mercer BM, et al. The Preterm Prediction Study: The value of new versus standard risk factors in predicting early and all spontaneous preterm births. Am J Public Health. 1998;88:233-38.